Abemaciclib + Aromatase Inhibitor + Abemaciclib + Fulvestrant
ApprovedRecruiting 0 watching 0 views this weekπ₯ Hot
85
Development Stage
β
Pre-clinicalβ
Phase 1β
Phase 2β
Phase 35
ApprovedIndication / Disease
Hormone Receptor-positive Metastatic Breast Cancer
Conditions
Hormone Receptor-positive Metastatic Breast Cancer, HER2-negative Metastatic Breast Cancer
Trial Timeline
Apr 27, 2022 β Apr 1, 2029
NCT ID
NCT05362760About Abemaciclib + Aromatase Inhibitor + Abemaciclib + Fulvestrant
Abemaciclib + Aromatase Inhibitor + Abemaciclib + Fulvestrant is a approved stage product being developed by Eli Lilly for Hormone Receptor-positive Metastatic Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05362760. Target conditions include Hormone Receptor-positive Metastatic Breast Cancer, HER2-negative Metastatic Breast Cancer.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05362760 | Approved | Recruiting |
Competing Products
20 competing products in Hormone Receptor-positive Metastatic Breast Cancer